{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:58:32Z","timestamp":1794412712773,"version":"4.9.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T00:00:00Z","timestamp":1609200000000},"content-version":"vor","delay-in-days":363,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Finnish Cancer Society"},{"DOI":"10.13039\/501100006196","name":"Oulun Yliopisto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2020]]},"DOI":"10.1136\/esmoopen-2020-000864","type":"journal-article","created":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T17:15:38Z","timestamp":1603300538000},"page":"e000864","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Tetracyclines increase the survival of NSCLC patients treated with EGFR TKIs: a retrospective nationwide registry study"],"prefix":"10.1016","volume":"5","author":[{"given":"Virve","family":"Alanen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanna","family":"Iivanainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martti","family":"Arffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6425-1640","authenticated-orcid":false,"given":"Jussi Pekka","family":"Koivunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/esmoopen-2020-000864_bb0010","author":"Shepherd"},{"key":"10.1136\/esmoopen-2020-000864_bb0015","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(05)67625-8","article-title":"Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa survival evaluation in lung cancer)","volume":"366","author":"Thatcher","year":"2005","journal-title":"The Lancet"},{"key":"10.1136\/esmoopen-2020-000864_bb0020","author":"Paez"},{"key":"10.1136\/esmoopen-2020-000864_bb0025","author":"Lynch"},{"key":"10.1136\/esmoopen-2020-000864_bb0030","article-title":"First-Line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer","volume":"28","author":"Greenhalgh","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1136\/esmoopen-2020-000864_bb0035","author":"Mok"},{"key":"10.1136\/esmoopen-2020-000864_bb0040","author":"Soria"},{"key":"10.1136\/esmoopen-2020-000864_bb0045","author":"Yang"},{"key":"10.1136\/esmoopen-2020-000864_bb0050","author":"Ding"},{"key":"10.1136\/esmoopen-2020-000864_bb0055","author":"Huang"},{"key":"10.1136\/esmoopen-2020-000864_bb0060","author":"Shah"},{"key":"10.1136\/esmoopen-2020-000864_bb0065","author":"Liu"},{"key":"10.1136\/esmoopen-2020-000864_bb0070","author":"Petrelli"},{"key":"10.1136\/esmoopen-2020-000864_bb0075","author":"Ocvirk"},{"key":"10.1136\/esmoopen-2020-000864_bb0080","author":"Hofheinz"},{"key":"10.1136\/esmoopen-2020-000864_bb0085","author":"Takeda"},{"key":"10.1136\/esmoopen-2020-000864_bb0090","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/S1556-0864(18)30424-6","volume":"13","author":"Gottfried","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1136\/esmoopen-2020-000864_bb0095","author":"Liao"},{"key":"10.1136\/esmoopen-2020-000864_bb0100","author":"Kudo"},{"key":"10.1136\/esmoopen-2020-000864_bb0105","author":"Petrelli"},{"key":"10.1136\/esmoopen-2020-000864_bb0110","author":"Califano"},{"key":"10.1136\/esmoopen-2020-000864_bb0115","author":"Hidalgo"},{"key":"10.1136\/esmoopen-2020-000864_bb0120","author":"Gordon"},{"key":"10.1136\/esmoopen-2020-000864_bb0125","author":"Goss"},{"key":"10.1136\/esmoopen-2020-000864_bb0130","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1200\/JCO.2015.62.3918","article-title":"Pan Canadian rash trial: a randomized phase III trial evaluating the impact of a prophylactic skin treatment regimen on epidermal growth factor receptor-tyrosine kinase Inhibitor\u2013Induced skin toxicities in patients with metastatic lung cancer","volume":"34","author":"Melosky","year":"2016","journal-title":"JCO"},{"key":"10.1136\/esmoopen-2020-000864_bb0135","author":"Arrieta"},{"key":"10.1136\/esmoopen-2020-000864_bb0140","author":"Lacouture"},{"key":"10.1136\/esmoopen-2020-000864_bb0145","author":"Ramalingam"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292032706X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292032706X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/esmoopen-2020-000864","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:23:39Z","timestamp":1761855819000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S205970292032706X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020]]}},"alternative-id":["S205970292032706X"],"URL":"https:\/\/doi.org\/10.1136\/esmoopen-2020-000864","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tetracyclines increase the survival of NSCLC patients treated with EGFR TKIs: a retrospective nationwide registry study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/esmoopen-2020-000864","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 THE AUTHORS. Published by Elsevier Limited on behalf of European Society for Medical Oncology; Originally published by BMJ.","name":"copyright","label":"Copyright"}],"article-number":"e000864"}}